Renewal of Charters for Certain Federal Advisory Committees, 74456-74458 [2016-25916]
Download as PDF
74456
Federal Register / Vol. 81, No. 207 / Wednesday, October 26, 2016 / Notices
revision of Vaccine Information
Statements; and recommending to the
Director of the National Vaccine
Program research related to vaccine
injuries which should be conducted to
carry out the VICP.
On July 21, 2016, the ACCV charter
was renewed. Renewal of the ACCV
charter gives authorization for the
Commission to operate until July 21,
2018.
A copy of the ACCV charter is
available on the ACCV Web site at
https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html. A copy of the charter also
can be obtained by accessing the FACA
database that is maintained by the
Committee Management Secretariat
under the General Services
Administration. The Web site address
for the FACA database is https://
www.facadatabase.gov/.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–25857 Filed 10–25–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Commission on Childhood
Vaccines
Health Resources and Service
Administration, HHS.
ACTION: Notice of meeting.
AGENCY:
In accordance with section
10(a)(2) of the Federal Advisory
Committee Act (Public Law 92–463),
notice is hereby given that a meeting is
scheduled for the Advisory Commission
on Childhood Vaccines (ACCV). This
meeting will be open to the public.
Information about the ACCV and the
agenda for this meeting can be obtained
by accessing the following Web site:
https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html.
DATES: The meeting will be held on
December 1 and 2, 2016, at 10:00 a.m.
EST.
ADDRESSES: This meeting will be held
via Adobe Connect Webinar. The public
can join the meeting by:
1. (Audio Portion) Calling the
conference phone number 800–779–
3561 and providing the following
information:
Leader Name: Dr. Narayan Nair.
Password: 8164763.
2. (Visual Portion) Connecting to the
ACCV Adobe Connect Pro Meeting
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:25 Oct 25, 2016
Jkt 241001
using the following URL: https://
hrsa.connectsolutions.com/accv/ (copy
and paste the link into your browser if
it does not work directly, and enter as
a guest). Participants should call and
connect 15 minutes prior to the meeting
in order for logistics to be set up. If you
have never attended an Adobe Connect
meeting, please test your connection
using the following URL: https://
hrsa.connectsolutions.com/common/
help/en/support/meeting_test.htm and
get a quick overview by following URL:
https://www.adobe.com/go/connectpro_
overview.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACCV should contact
Annie Herzog, Program Analyst,
Division of Injury Compensation
Programs (DICP), Health Resources and
Services Administration in one of three
ways: (1) Send a request to the following
address: Annie Herzog, Program
Analyst, DICP, Health Resources and
Services Administration, 5600 Fishers
Lane, 08N146B, Rockville, Maryland
20857; (2) call (301) 443–6593; or (3)
send an email to aherzog@hrsa.gov.
At this time the meeting is scheduled
to be held over 2 days via conference
call and Adobe Connect webinar;
however, meeting times and locations
could change. For the latest information
regarding meeting start time and
location, please check the ACCV Web
site: https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html.
SUPPLEMENTARY INFORMATION: The ACCV
was established by section 2119 of the
Public Health Service Act (the Act) (42
U.S.C. 300aa–19), as enacted by Public
Law (Pub. L.) 99–660, and as
subsequently amended, and advises the
Secretary of Health and Human Services
(the Secretary) on issues related to
implementation of the National Vaccine
Injury Compensation Program (VICP).
Other activities of ACCV include:
Recommending changes to the Vaccine
Injury Table at its own initiative or as
the result of the filing of a petition;
advising the Secretary in implementing
section 2127 of the Act regarding the
need for childhood vaccination
products that result in fewer or no
significant adverse reactions; surveying
federal, state, and local programs and
activities related to gathering
information on injuries associated with
the administration of childhood
vaccines, including the adverse reaction
reporting requirements of section
2125(b) of the Act; advising the
Secretary on the methods of obtaining,
compiling, publishing, and using
credible data related to the frequency
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
and severity of adverse reactions
associated with childhood vaccines;
consulting on the development or
revision of Vaccine Information
Statements; and recommending to the
Director of the National Vaccine
Program research related to vaccine
injuries which should be conducted to
carry out VICP.
The agenda items for the December
2016 meeting will include, but are not
limited to, updates from the Division of
Injury Compensation Programs (DICP),
Department of Justice (DOJ), National
Vaccine Program Office (NVPO),
Immunization Safety Office (Centers for
Disease Control and Prevention),
National Institute of Allergy and
Infectious Diseases (National Institutes
of Health) and Center for Biologics,
Evaluation and Research (Food and
Drug Administration). A draft agenda
and additional meeting materials will be
posted on the ACCV Web site (https://
www.hrsa.gov/advisorycommittees/
childhoodvaccines/) prior to
the meeting. Agenda items are subject to
change as priorities dictate.
Members of the public will have the
opportunity to provide comments. Oral
comments will be honored in the order
they are requested and may be limited
as time allows. Requests to make oral
comments or provide written comments
to the ACCV should be sent to Annie
Herzog using the address and phone
number above by November 29, 2016.
Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify Annie
Herzog, using the address and phone
number above at least 10 days prior to
the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–25875 Filed 10–25–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Renewal of Charters for Certain
Federal Advisory Committees
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, as amended (5
U.S.C. App), the U.S. Department of
Health and Human Services is hereby
announcing that the charters have been
renewed for the following federal
advisory committees for which Office of
SUMMARY:
E:\FR\FM\26OCN1.SGM
26OCN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 207 / Wednesday, October 26, 2016 / Notices
the Assistant Secretary for Health
provides management support: Chronic
Fatigue Syndrome Advisory Committee
(CFSAC); President’s Council on
Fitness, Sports, and Nutrition (PCFSN;
the Council); Secretary’s Advisory
Committee on Human Research
Protections (SACHRP); and Advisory
Committee on Blood and Tissue Safety
and Availability (ACBTSA).
Functioning as federal advisory
committees, these committees are
governed by the provisions of the
Federal Advisory Committee Act
(FACA). Under FACA, it is stipulated
that the charter for a federal advisory
committee must be renewed every two
years in order for the committee to
continue to operate.
FOR FURTHER INFORMATION CONTACT: Olga
B. Nelson, Committee Management
Officer, Office of the Assistant Secretary
for Health; U.S. Department of Health
and Human Services; 200 Independence
Avenue SW., Room 714B; Washington,
DC 20201; (202) 690–5205.
SUPPLEMENTARY INFORMATION: CFSAC
was established on September 5, 2002 as
a discretionary federal advisory
committee. The Committee provides
science-based advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health, on a
broad range of issues and topics
pertaining to myalgic
encephalomyelitis/chronic fatigue
syndrome (ME/CFS), including (1)
opportunities to improve knowledge
and research about the epidemiology,
etiologies, biomarkers and risk factors
for ME/CFS; (2) research on the
diagnosis, treatment, and management
of ME/CFS and potential impact of
treatment options; (3) strategies to
inform the public, health care
professionals, and the biomedical
academic and research communities
about ME/CFS advances; (4)
partnerships to improve the quality of
life of ME/CFS patients; and (5)
strategies to insure that input from ME/
CFS patients and care givers is
incorporated into HHS policy and
research.
The new charter includes the
following amendments: (1) The
language in the Description of Duties
has been simplified. A fifth duty has
been added to emphasize the
importance of getting stakeholder input
on HHS policy and research concerning
ME/CFS; (2) authority has been given to
the Assistant Secretary for Health (ASH)
as an official to whom the Committee
will report. Extending this authority to
include the ASH gives clear
responsibility to the ASH for better
VerDate Sep<11>2014
18:25 Oct 25, 2016
Jkt 241001
monitoring and implementation of the
recommendations that are approved by
the Secretary; and (3) the Committee
structure has been changed to (a)
increase the number of voting public
members to 13 to give patients and/or
caretakers of ME/CFS more
representation on the Committee. This
amendment has been made to the
charter to respond to recent concerns
that had been expressed by CFS
advocates, (b) remove the Centers for
Medicare and Medicaid Services (CMS)
as a non-voting ex-officio member. A
determination was made that there is
not much for CMS to contribute to or to
seek advice from CFSAC. It would be
more beneficial to have CMS involved
in the Committee’s deliberative process
if diagnostics or treatments are
developed for ME/CFS. This activity is
not projected to take place during the
two-year period that the new charter
will be in effect, and (c) expand the
Committee structure to add two new exofficio positions for the Department of
Veterans Affairs (VA) and the
Department of Defense (DoD).
Expanding the Committee structure to
include these two government agencies
will provide valuable information on
services available to patients with ME/
CFS and research being conducted on
illnesses with similar symptoms to ME/
CFS.
On September 5, 2016, the Secretary
of Health and Human Services approved
for the CFSAC charter with the
proposed amendments to be renewed.
The new charter has been made
effective; the charter was filed with the
appropriate Congressional committees
and the Library of Congress on
September 5, 2016. Renewal of the
CFSAC charter provides authorization
for the Committee to continue to operate
until September 5, 2018. A copy of the
Committee charter is available on the
CFSAC Web site at https://www.hhs.gov/
advcomcfs.
The PCFSN is a non-discretionary
federal advisory committee. The PCFSN
was established under Executive Order
13545, dated June 22, 2010. This
authorizing directive was issued to
amend the purpose, function, and name
of the Council, which formerly operated
as the President’s Council on Physical
Fitness and Sports (PCPFS). The scope
of the Council was changed to include
nutrition to bring attention to the
importance of good nutritional habits
with regular physical activity for
maintaining a healthy lifestyle. The
PCFSN is the only federal advisory
committee that is focused solely on the
promotion of physical activity, fitness,
sports, and nutrition. Since the PCFSN
was established by Presidential
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
74457
directive, appropriate action had to be
taken by the President or agency head
to authorize continuation of the PCFSN.
The President issued Executive Order
13708, dated September 30, 2015. Under
the authority given in this directive, the
Council can continue to operate until
September 30, 2017.
No amendments were recommended
for the PCFSN charter. The charter was
approved by the Secretary of Health and
Human Services on September 8, 2016,
and it was filed with the appropriate
Congressional committees and the
Library of Congress on September 10,
2016. A copy of the Council charter is
available on the PCFSN Web site at
https://fitness.gov.
SACHRP is a discretionary federal
advisory committee. SACHRP provides
advice to the Secretary, through the
Assistant Secretary for Health, on
matters pertaining to the continuance
and improvement of functions within
the authority of the Department of
Health and Human Services concerning
protections for human subjects in
research.
There was one amendment
recommended and approved for the
SACHRP charter. The charter stipulated
that appointment of the Designated
Federal Officer (DFO) was restricted to
the Director of the Office for Human
Research Protections. This restriction
has been removed to allow for other
senior level program and management
OHRP staff to be considered for
appointment as the DFO. On September
30, 2016, the Secretary of Health and
Human Services approved for the
SACHRP charter to be renewed. The
new charter was filed with the
appropriate Congressional committees
and the Library of Congress on October
1, 2016. SACHRP is authorized to
continue to operate until October 1,
2018. A copy of the charter is available
on the Committee Web site at https://
www.hhs.gov/ohrp/sachrp/.
The ACBTSA is a discretionary
federal advisory committee. The
Committee provides advice to the
Secretary, through the Assistant
Secretary for Health, on a range of
policy issues related to the safety of
blood, blood products, organs and
tissues. For organs and blood stem cells,
the Committee’s work is limited to
policy issues related to donor derived
infectious disease complications of
transplantation around the safety and
availability of the blood supply and
blood products.
There were two minor amendments
recommended and approved for the
ACBTSA charter. The charter has been
amended to include the option for a
Vice Chair and/or Co-Chairs to be
E:\FR\FM\26OCN1.SGM
26OCN1
74458
Federal Register / Vol. 81, No. 207 / Wednesday, October 26, 2016 / Notices
appointed for the Committee leadership.
The Committee structure has been
expanded to include ex-officio
representation from the Department of
Veterans Affairs (VA). The VA has the
largest conglomerate of hospitals in the
United States. The agency has
responsibility for the largest patient
population that uses the largest quantity
of blood and tissue products in the
United States. Therefore, it was
determined that involvement of the VA
would be beneficial to the ACBTSA for
ensuring that the Committee properly
addresses current issues and concerns
regarding blood and tissue safety and
availability.
On October 5, 2016, the new charter
for the ACBTSA was approved by the
Secretary of Health and Human
Services, and it was filed with the
appropriate Congressional committees
and the Library of Congress on October
9, 2016. ACBTSA is authorized to
operate until October 9, 2018. A copy of
the charter can be obtained on the
ACBTSA Web site at https://
www.hhs.gov/ash/bloodsafety.
Copies of the charters for the
designated committees also can be
obtained by accessing the FACA
database that is maintained by the
Committee Management Secretariat
under the General Services
Administration. The Web site address
for the FACA database is https://
facadatabase.gov/.
Dated: October 20, 2016.
Karen B. DeSalvo,
Acting Assistant Secretary for Health.
[FR Doc. 2016–25916 Filed 10–25–16; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Short-Term Alternative Animal Models
or In Vitro Tests Used To Identify
Substances With the Potential To
Cause Excessive Inflammation or
Exaggerated Immune Responses;
Request for Information
The National Toxicology
Program (NTP) at the National Institute
of Environmental Health Sciences
(NIEHS) requests available data and
information on approaches and/or
technologies currently used to identify
substances with the potential to cause
excessive inflammation or exaggerated
immune responses leading to tissue
injury when swallowed, inhaled, or
absorbed through the skin. Submitted
information will be used to assess the
state of the science and determine
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:25 Oct 25, 2016
Jkt 241001
technical needs for non-animal test
methods that could be used to evaluate
the potential of chemicals to induce
inflammation and immune-related
conditions.
Receipt of information: Deadline
is December 12, 2016.
ADDRESSES: Data and information
should be submitted electronically at
https://ntp.niehs.nih.gov/go/input.
FOR FURTHER INFORMATION CONTACT: Dr.
Dori Germolec, Toxicology Branch,
Division of NTP, NIEHS; email:
germolec@niehs.nih.gov; telephone:
(919) 541–3230.
SUPPLEMENTARY INFORMATION:
Background: NTP has an interest in
developing more efficient and scalable
test platforms to provide the scientific
basis for predictive models of chemical
effects on human disease. Short-term
toxicity tests may be conducted to
determine the potential for a single or
short-term dose of a substance to cause
inflammation-related responses or
impact local and systemic immune
function when inhaled (inhalation
toxicity testing), swallowed (oral
toxicity testing), or absorbed through the
skin (dermal toxicity testing). A number
of observations support a role for
environmental influences on
inflammatory and immune-related
diseases such as diabetes. One specific
use of information received in response
to this request is to assist NTP in
identifying in vitro or alternative animal
model screens that might be used to
assess the potential for chemicals to
cause outcomes related to Type 1
diabetes. In addition, information
received from this request will provide
fundamental knowledge on the use of
these in vitro platforms for identifying
environmental triggers of excessive
inflammation and exaggerated immune
responses that could lead to tissue
injury.
Request for Information: NTP requests
available data and information on
approaches and/or technologies
currently used to identify substances
with the potential to cause excessive
inflammation or exaggerated immune
responses leading to tissue injury.
Respondents should provide
information on any activities relevant to
the development or validation of
alternatives to in vivo tests currently
used in the assessment of immune
toxicity and autoimmunity.
Respondents to this request for
information should include their name,
affiliation (if applicable), mailing
address, telephone, email, and
sponsoring organization (if any) with
their communications. The deadline for
DATES:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
receipt of the requested information is
December 12, 2016.
Responses to this request are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in responses. This
request for information is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on NTP: NTP
is an interagency program established in
1978 (43 FR 53060) to strengthen the
Department’s activities in toxicology
research and testing and to develop and
validate new and better testing methods.
Other activities of the program focus on
strengthening the science base in
toxicology and providing information
about potentially toxic chemicals to
health-regulatory and research agencies,
scientific and medical communities,
and the public. NTP is located
administratively at the NIEHS.
Information about NIEHS and NTP is
available at https://www.niehs.nih.gov
and https://ntp.niehs.nih.gov,
respectively.
Dated: October 20, 2016.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2016–25924 Filed 10–25–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\26OCN1.SGM
26OCN1
Agencies
[Federal Register Volume 81, Number 207 (Wednesday, October 26, 2016)]
[Notices]
[Pages 74456-74458]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-25916]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Renewal of Charters for Certain Federal Advisory Committees
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, as
amended (5 U.S.C. App), the U.S. Department of Health and Human
Services is hereby announcing that the charters have been renewed for
the following federal advisory committees for which Office of
[[Page 74457]]
the Assistant Secretary for Health provides management support: Chronic
Fatigue Syndrome Advisory Committee (CFSAC); President's Council on
Fitness, Sports, and Nutrition (PCFSN; the Council); Secretary's
Advisory Committee on Human Research Protections (SACHRP); and Advisory
Committee on Blood and Tissue Safety and Availability (ACBTSA).
Functioning as federal advisory committees, these committees are
governed by the provisions of the Federal Advisory Committee Act
(FACA). Under FACA, it is stipulated that the charter for a federal
advisory committee must be renewed every two years in order for the
committee to continue to operate.
FOR FURTHER INFORMATION CONTACT: Olga B. Nelson, Committee Management
Officer, Office of the Assistant Secretary for Health; U.S. Department
of Health and Human Services; 200 Independence Avenue SW., Room 714B;
Washington, DC 20201; (202) 690-5205.
SUPPLEMENTARY INFORMATION: CFSAC was established on September 5, 2002
as a discretionary federal advisory committee. The Committee provides
science-based advice and recommendations to the Secretary of Health and
Human Services, through the Assistant Secretary for Health, on a broad
range of issues and topics pertaining to myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS), including (1) opportunities to
improve knowledge and research about the epidemiology, etiologies,
biomarkers and risk factors for ME/CFS; (2) research on the diagnosis,
treatment, and management of ME/CFS and potential impact of treatment
options; (3) strategies to inform the public, health care
professionals, and the biomedical academic and research communities
about ME/CFS advances; (4) partnerships to improve the quality of life
of ME/CFS patients; and (5) strategies to insure that input from ME/CFS
patients and care givers is incorporated into HHS policy and research.
The new charter includes the following amendments: (1) The language
in the Description of Duties has been simplified. A fifth duty has been
added to emphasize the importance of getting stakeholder input on HHS
policy and research concerning ME/CFS; (2) authority has been given to
the Assistant Secretary for Health (ASH) as an official to whom the
Committee will report. Extending this authority to include the ASH
gives clear responsibility to the ASH for better monitoring and
implementation of the recommendations that are approved by the
Secretary; and (3) the Committee structure has been changed to (a)
increase the number of voting public members to 13 to give patients
and/or caretakers of ME/CFS more representation on the Committee. This
amendment has been made to the charter to respond to recent concerns
that had been expressed by CFS advocates, (b) remove the Centers for
Medicare and Medicaid Services (CMS) as a non-voting ex-officio member.
A determination was made that there is not much for CMS to contribute
to or to seek advice from CFSAC. It would be more beneficial to have
CMS involved in the Committee's deliberative process if diagnostics or
treatments are developed for ME/CFS. This activity is not projected to
take place during the two-year period that the new charter will be in
effect, and (c) expand the Committee structure to add two new ex-
officio positions for the Department of Veterans Affairs (VA) and the
Department of Defense (DoD). Expanding the Committee structure to
include these two government agencies will provide valuable information
on services available to patients with ME/CFS and research being
conducted on illnesses with similar symptoms to ME/CFS.
On September 5, 2016, the Secretary of Health and Human Services
approved for the CFSAC charter with the proposed amendments to be
renewed. The new charter has been made effective; the charter was filed
with the appropriate Congressional committees and the Library of
Congress on September 5, 2016. Renewal of the CFSAC charter provides
authorization for the Committee to continue to operate until September
5, 2018. A copy of the Committee charter is available on the CFSAC Web
site at https://www.hhs.gov/advcomcfs.
The PCFSN is a non-discretionary federal advisory committee. The
PCFSN was established under Executive Order 13545, dated June 22, 2010.
This authorizing directive was issued to amend the purpose, function,
and name of the Council, which formerly operated as the President's
Council on Physical Fitness and Sports (PCPFS). The scope of the
Council was changed to include nutrition to bring attention to the
importance of good nutritional habits with regular physical activity
for maintaining a healthy lifestyle. The PCFSN is the only federal
advisory committee that is focused solely on the promotion of physical
activity, fitness, sports, and nutrition. Since the PCFSN was
established by Presidential directive, appropriate action had to be
taken by the President or agency head to authorize continuation of the
PCFSN. The President issued Executive Order 13708, dated September 30,
2015. Under the authority given in this directive, the Council can
continue to operate until September 30, 2017.
No amendments were recommended for the PCFSN charter. The charter
was approved by the Secretary of Health and Human Services on September
8, 2016, and it was filed with the appropriate Congressional committees
and the Library of Congress on September 10, 2016. A copy of the
Council charter is available on the PCFSN Web site at https://fitness.gov.
SACHRP is a discretionary federal advisory committee. SACHRP
provides advice to the Secretary, through the Assistant Secretary for
Health, on matters pertaining to the continuance and improvement of
functions within the authority of the Department of Health and Human
Services concerning protections for human subjects in research.
There was one amendment recommended and approved for the SACHRP
charter. The charter stipulated that appointment of the Designated
Federal Officer (DFO) was restricted to the Director of the Office for
Human Research Protections. This restriction has been removed to allow
for other senior level program and management OHRP staff to be
considered for appointment as the DFO. On September 30, 2016, the
Secretary of Health and Human Services approved for the SACHRP charter
to be renewed. The new charter was filed with the appropriate
Congressional committees and the Library of Congress on October 1,
2016. SACHRP is authorized to continue to operate until October 1,
2018. A copy of the charter is available on the Committee Web site at
https://www.hhs.gov/ohrp/sachrp/.
The ACBTSA is a discretionary federal advisory committee. The
Committee provides advice to the Secretary, through the Assistant
Secretary for Health, on a range of policy issues related to the safety
of blood, blood products, organs and tissues. For organs and blood stem
cells, the Committee's work is limited to policy issues related to
donor derived infectious disease complications of transplantation
around the safety and availability of the blood supply and blood
products.
There were two minor amendments recommended and approved for the
ACBTSA charter. The charter has been amended to include the option for
a Vice Chair and/or Co-Chairs to be
[[Page 74458]]
appointed for the Committee leadership. The Committee structure has
been expanded to include ex-officio representation from the Department
of Veterans Affairs (VA). The VA has the largest conglomerate of
hospitals in the United States. The agency has responsibility for the
largest patient population that uses the largest quantity of blood and
tissue products in the United States. Therefore, it was determined that
involvement of the VA would be beneficial to the ACBTSA for ensuring
that the Committee properly addresses current issues and concerns
regarding blood and tissue safety and availability.
On October 5, 2016, the new charter for the ACBTSA was approved by
the Secretary of Health and Human Services, and it was filed with the
appropriate Congressional committees and the Library of Congress on
October 9, 2016. ACBTSA is authorized to operate until October 9, 2018.
A copy of the charter can be obtained on the ACBTSA Web site at https://www.hhs.gov/ash/bloodsafety.
Copies of the charters for the designated committees also can be
obtained by accessing the FACA database that is maintained by the
Committee Management Secretariat under the General Services
Administration. The Web site address for the FACA database is https://facadatabase.gov/.
Dated: October 20, 2016.
Karen B. DeSalvo,
Acting Assistant Secretary for Health.
[FR Doc. 2016-25916 Filed 10-25-16; 8:45 am]
BILLING CODE 4150-28-P